|

ArabinoFuranosylGuanine [18F]F-AraG Clinical Trials

2 actively recruiting trials across 1 location

Pipeline

Phase 1: 1Phase 1/2: 1

Top Sponsors

  • M.D. Anderson Cancer Center2

Indications

  • Cancer2
  • Clear Cell Renal Cell Carcinoma1
  • Advanced Cancer1
  • Esophageal Cancer1

Houston, Texas2 trials

18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer

MD Anderson Cancer Center

Phase 1
Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC

MD Anderson Cancer Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.